Breakthrough Therapy Status for LSD Formulation to Treat Generalized Anxiety Disorder

SOURCE www.cnn.com
A clinical trial's positive results led to an LSD formulation receiving breakthrough therapy status from the FDA for treating generalized anxiety disorder. The drug by Mind Medicine Inc. showed promising efficacy and safety in phase 2b trials.

Key Points

  • FDA granted breakthrough therapy status to MM120 for generalized anxiety disorder
  • MM120 showed 48% remission rate and improved symptoms for 65% of patients in phase 2b trial
  • Still needs to undergo standard FDA approval process including phase III trials

Pros

  • Positive results from clinical trials
  • Recognition by FDA for meeting unmet medical need

Cons

  • Possible adverse effects like illusions, hallucinations, and anxiety